- Home
- DLXY vs SNGX Comparison
DLXY vs SNGX Comparison
Compare DLXY & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLXY
- SNGX
- Stock Information
- Founded
- DLXY 2007
- SNGX 1987
- Country
- DLXY Singapore
- SNGX United States
- Employees
- DLXY N/A
- SNGX N/A
- Industry
- DLXY
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- DLXY
- SNGX Health Care
- Exchange
- DLXY Nasdaq
- SNGX Nasdaq
- Market Cap
- DLXY 13.9M
- SNGX 13.8M
- IPO Year
- DLXY 2025
- SNGX 1987
- Fundamental
- Price
- DLXY $0.96
- SNGX $1.48
- Analyst Decision
- DLXY
- SNGX Strong Buy
- Analyst Count
- DLXY 0
- SNGX 1
- Target Price
- DLXY N/A
- SNGX $6.00
- AVG Volume (30 Days)
- DLXY 61.4K
- SNGX 256.3K
- Earning Date
- DLXY 12-05-2025
- SNGX 11-07-2025
- Dividend Yield
- DLXY N/A
- SNGX N/A
- EPS Growth
- DLXY N/A
- SNGX N/A
- EPS
- DLXY 0.07
- SNGX N/A
- Revenue
- DLXY $314,916,000.00
- SNGX N/A
- Revenue This Year
- DLXY N/A
- SNGX N/A
- Revenue Next Year
- DLXY N/A
- SNGX N/A
- P/E Ratio
- DLXY $15.03
- SNGX N/A
- Revenue Growth
- DLXY 8.90
- SNGX N/A
- 52 Week Low
- DLXY $0.64
- SNGX $1.09
- 52 Week High
- DLXY $7.16
- SNGX $6.23
- Technical
- Relative Strength Index (RSI)
- DLXY N/A
- SNGX 47.15
- Support Level
- DLXY N/A
- SNGX $1.25
- Resistance Level
- DLXY N/A
- SNGX $1.47
- Average True Range (ATR)
- DLXY 0.00
- SNGX 0.11
- MACD
- DLXY 0.00
- SNGX 0.02
- Stochastic Oscillator
- DLXY 0.00
- SNGX 65.45
About DLXY Delixy Holdings Limited Ordinary Shares
Delixy Holdings Ltd a holding company that operates through subsidiary. It is engaged in the trading of oil-related products, which can be categorized into crude oil, and oil-based products such as naphtha, motor gasoline, gas oil, fuel oil, asphalt, base oil, and other petrochemicals. The company has two reportable segments: the Sale of crude oil and the Sale of oil-based products. Key revenue is generated from the Sale of crude oil.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).